 Uric Acid
"Uric Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
| Descriptor ID |
D014527
|
| MeSH Number(s) |
D03.132.960.877 D03.438.759.758.824.877
|
| Concept/Terms |
Uric Acid- Uric Acid
- Acid, Uric
- Trioxopurine
- 2,6,8-Trihydroxypurine
Sodium Urate Monohydrate- Sodium Urate Monohydrate
- Monohydrate, Sodium Urate
- Urate Monohydrate, Sodium
- Monosodium Urate Monohydrate
- Monohydrate, Monosodium Urate
- Urate Monohydrate, Monosodium
- Sodium Acid Urate Monohydrate
- Sodium Urate
- Urate, Sodium
- Monosodium Urate
- Urate, Monosodium
- Sodium Acid Urate
- Acid Urate, Sodium
- Urate, Sodium Acid
|
Below are MeSH descriptors whose meaning is more general than "Uric Acid".
Below are MeSH descriptors whose meaning is more specific than "Uric Acid".
This graph shows the total number of publications written about "Uric Acid" by people in this website by year, and whether "Uric Acid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 4 | 7 | | 1981 | 1 | 1 | 2 | | 1982 | 1 | 4 | 5 | | 1983 | 1 | 1 | 2 | | 1984 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1986 | 0 | 2 | 2 | | 1988 | 2 | 0 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 4 | 4 | | 1992 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 3 | 4 | | 2002 | 0 | 3 | 3 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 3 | 5 | | 2006 | 1 | 2 | 3 | | 2008 | 2 | 4 | 6 | | 2009 | 2 | 3 | 5 | | 2010 | 2 | 3 | 5 | | 2011 | 4 | 2 | 6 | | 2012 | 2 | 3 | 5 | | 2013 | 1 | 4 | 5 | | 2014 | 1 | 3 | 4 | | 2015 | 2 | 2 | 4 | | 2017 | 2 | 2 | 4 | | 2018 | 0 | 2 | 2 | | 2019 | 0 | 2 | 2 | | 2020 | 1 | 1 | 2 | | 2021 | 2 | 2 | 4 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Uric Acid" by people in Profiles.
-
Wang J, Liu K, Xiao T, Liu P, Prinz RA, Xu X. Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-ß-activated kinase 1. Oncoimmunology. 2022; 11(1):2016159.
-
Anderson IJ, Davis AM, Jan RH. Management of Gout. JAMA. 2021 Dec 28; 326(24):2519-2520.
-
Bakris GL, Mikami H, Hirata M, Nakajima A, Cressman MD. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 Aug 26; 2(8):1240-1250.
-
Chen B, Lu C, Gu HQ, Li Y, Zhang G, Lio J, Luo X, Zhang L, Hu Y, Lan X, Chen Z, Xie Q, Pan H. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne). 2021; 12:633767.
-
Sinnott-Armstrong N, Naqvi S, Rivas M, Pritchard JK. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. Elife. 2021 02 15; 10.
-
Evan AP, Coe FL, Worcester EM, Williams JC, Heiman J, Bledsoe S, Sommer A, Philips CL, Lingeman JE. Discrepancy Between Stone and Tissue Mineral Type in Patients with Idiopathic Uric Acid Stones. J Endourol. 2020 03; 34(3):385-393.
-
Borofsky MS, Handa RK, Evan AP, Williams JC, Bledsoe S, Coe FL, Worcester EM, Lingeman JE. In Vivo Renal Tubule pH in Stone-Forming Human Kidneys. J Endourol. 2020 02; 34(2):203-208.
-
Asplin JR, Goldfarb DS. Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019 05; 95(5):1022-1024.
-
Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
-
Bergsland KJ, Coe FL, Parks JH, Asplin JR, Worcester EM. Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers. Nephrol Dial Transplant. 2018 05 01; 33(5):759-770.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|